In conclusion, lung cancer is a leading cause of cancer-specific mortality around the world and with the rapid development of liquid biopsy, CTCs and ctDNA provide a novel method for assaying KRAS mutations in lung cancer. This evidence concerns the gene KRAS and lung carcinoma.